Outcomes of COVID-19 in children and adolescents with cancer
Previous studies have shown that children with COVID-19 generally have a milder disease course compared to adults.
Delta doubles risk of hospitalization compared to Alpha, study finds
New research out of England published in The Lancet Infectious Diseases suggests that hospitalization and visits to the emergency department are twice as likely with the variant of concern (VOC) Delta compared to the Alpha variant.
Administering a third booster shot: an ethical dilemma
While countries around the world are working to get their populations vaccinated, the emergence of SARS-CoV-2 variants of concern (VOCs) has threatened our return to normalcy.
A snapshot of the current landscape of COVID-19 vaccines
As the world – and Canada – deals with increasing case numbers due to variants, scientists from the Imperial College London provide a snapshot of emerging data on real-life efficacy of COVID-19 vaccines against variants.
Another tool to combat COVID-19: the Moderna vaccine is shown to be safe and efficacious among adolescents 12-17 years of age
In their recent publication in The New England Journal of Medicine, researchers Dr. Kashir Ali, Dr. Gary Berman and colleagues presented the interim results of the Moderna vaccine trial in adolescents aged 12 to 17.
Back-to-university checklist: books, pens, vaccine
Researchers from Ontario indicate that about 80% of students enrolled at a large Canadian university between June and October 2020, prior to the availability of vaccines, intended to receive a COVID-19 vaccine once it was offered.
Safety and immunogenicity of a “mix-and-match” vaccine strategy with the AstraZeneca and Pfizer-BioNTech vaccines
A new study published in The Lancet by researchers from Oxford University provides more in-depth safety and immunogenicity data to support a “mix-and-match” vaccine strategy, similar to the one currently used in Canada.
Breakthrough infections with the Delta variant in vaccinated individuals may be associated with lower levels of neutralizing antibodies.
Emergence of variants of concern (VOCs) may potentially impact efforts to end the COVID-19 pandemic, despite the ongoing continuation of the global vaccine rollout.
Meeting the need for Long COVID policies – call for action
According to a recent viewpoint in Science, around one in three people with symptomatic COVID-19 still experience symptoms 12 weeks after the onset of infection, an outcome known as Post-COVID Conditions or Long COVID.